Both authors contributed equally.
Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability
Article first published online: 29 SEP 2011
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction
Volume 18, Issue 6, pages 908–911, November 2013
How to Cite
Crunelle, C. L., van de Giessen, E., Schulz, S., Vanderschuren, L. J. M. J., de Bruin, K., van den Brink, W. and Booij, J. (2013), Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability. Addiction Biology, 18: 908–911. doi: 10.1111/j.1369-1600.2011.00369.x
- Issue published online: 28 NOV 2013
- Article first published online: 29 SEP 2011
- Academic Medical Center
- ZonMW/NIDA. Grant Number: nr 311-80-003
- Cannabinoid 1 receptor;
- dopamine D2 receptor;
- nucleus accumbens;
The cannabinoid 1 receptor antagonist rimonabant (SR141716) alters rewarding properties and intake of food and drugs. Additionally, striatal dopamine D2 receptor (DRD2) availability has been implicated in reward function. This study shows that chronic treatment of rats with rimonabant (1.0 and 3.0 mg/kg/day) dose-dependently increased DRD2 availability in the dorsal striatum (14 and 23%) compared with vehicle. High-dose rimonabant also increased DRD2 availability in the ventral striatum (12%) and reduced weight gain. Thus, up-regulation of striatal DRD2 by chronic rimonabant administration may be an underlying mechanism of action and confirms the interactions of the endocannabinoid and dopaminergic systems.